MaxCyte Q2 FY26 net loss narrows 28% to $8.9 million; revenue drops 15% to $7.3 million
MXCT•Margins and expenses improve
Gross profit slipped to $5.6 million, cutting gross margin to 77% from 82% a year earlier.
Operating expenses dropped to $15.8 million from $21.2 million. Cash, cash equivalents and investments totaled $141.9 million.
Q2 revenue and loss narrow, but sales decline
MaxCyte posted Q2 2026 revenue of $7.3 million, down 15% from Q2 2025; net loss narrowed to $8.9 million.
Core revenue fell 21% to $6.5 million. SPL Program-related revenue rose to $0.8 million from $0.3 million.
Guidance reiterated and Genentech partnership disclosed
MaxCyte reiterated 2026 revenue guidance of $30 million to $32 million.
The company also disclosed a multi-platform license partnership with Genentech.
